Table 2.
Summary of clinical and pathological features of the studied HPV-associated OPSCC cohorts
| Variable | Cohort |
|||||
|---|---|---|---|---|---|---|
| D1 | D2 | D3 | D4 | D5 | D6 | |
| Total patients, No. (%) | 94 (21.4) | 51 (11.6) | 45 (10.3) | 66 (15.0) | 123 (28.0) | 60 (13.7) |
| Median follow-up, mo | 57.65 | 52.14 | 45.8 | 83.67 | 65.79 | 70.59 |
| Age, No. (%), y | ||||||
| > 55 | 67 (71.3) | 28 (54.9) | 23 (51.1) | 30 (45.5) | 80 (65.0) | 29 (48.3) |
| ≤ 55 | 27 (28.7) | 23 (45.1) | 22 (48.9) | 36 (54.6) | 43 (35.0) | 31 (51.7) |
| Race, No. (%) | ||||||
| Caucasian | — | 48 (94.1) | 43 (95.6) | 62 (93.9) | 117 (95.1) | 58 (96.7) |
| Non-Caucasian | — | 3 (5.9) | 2 (4.4) | 4 (6.1) | 6 (4.9) | 2 (3.3) |
| No data | 94 (100) | — | — | — | — | — |
| Sex, No. (%) | ||||||
| Male | 93 (98.9) | 45 (88.2) | 37 (82.2) | 57 (86.4) | 110 (89.4) | 54 (90.0) |
| Female | 1 (1.1) | 6 (11.8) | 8 (17.8) | 9 (13.6) | 13 (10.6) | 6 (10.0) |
| Smoking pack-years, No. (%) | ||||||
| 0 | 17 (18.1) | 21 (41.2) | 23 (51.1) | 23 (34.9) | 59 (48.0) | 39 (65.0) |
| 1–10 | 10 (10.6) | 18 (35.3) | 14 (31.1) | 13 (19.7) | 24 (19.5) | 6 (10.0) |
| 11–30 | 24 (25.5) | 12 (23.5) | 8 (17.8) | 30 (45.5) | 40 (32.5) | 15 (25.0) |
| No data | 2 (2.1) | — | — | — | — | — |
| Overall stage by AJCC 8th edition, No. (%) | ||||||
| I | 16 (17.0) | 51 (100) | 45 (100) | 66 (100) | 123 (100) | 60 (100) |
| II/III/IV | 78 (83.0) | — | — | — | — | — |
| T stage, No. (%) | ||||||
| T1/T2 | 55 (58.5) | 51 (100) | 45 (100) | 66 (100) | 123 (100) | 55 (91.7) |
| T3/T4 | 39 (41.5) | — | — | — | — | — |
| No data | — | — | — | — | — | 5 (8.3) |
| N stage, No. (%) | ||||||
| N0/N1 | 23 (24.5) | 51 (100) | 45 (100) | 66 (100) | 123 (100) | 58 (96.7) |
| N2/N3 | 71 (75.5) | — | — | — | — | — |
| No data | — | — | — | — | — | 2 (3.3) |
| Treatment, No. (%) | ||||||
| Surgery + adjuvant therapy | 3 (3.2) | 15 (29.4) | 30 (66.7) | 66 (100) | — | 25 (41.7) |
| Surgery alone | — | 1 (2.0) | 13 (28.9) | — | — | 6 (10.0) |
| Primary chemoradiation | 91 (96.8) | 35 (68.6) | 2 (4.4) | — | 123 (100) | 26 (43.3) |
| No data | — | — | — | — | — | 3 (5.0) |
a
AJCC = American Joint Committee on Cancer; HPV = human papillomavirus; OPSCC = oropharyngeal squamous cell carcinoma.